The effect of intravenous combined application of dexamethasone and dexmedetomidine on postoperative rebound pain in patients with brachial plexus block: A randomized, double-blind, controlled trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2600121570

Enrollment

Unknown

Registered

2026-04-01

Start date

2026-04-01

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rebound pain after nerve block wears off.

Interventions

The dexmedetomidine group (Group D2):Normal saline 3 ml IV and dexmedetomidine 1 µg/kg IV infusion

The control group (Group C):Normal saline 3 ml IV and normal saline 20 ml IV infusion

The dexamethasone group (Group D1):Dexamethasone 15 mg IV and normal saline 20 ml IV infusion

The dexamethasone plus dexmedetomidine group (Group D3).:Dexamethasone 15 mg IV and dexmedetomidine 1 µg/kg IV infusion.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled for elective upper limb long bone internal fixation or rotator cuff repair under general anesthesia combined with brachial plexus block. 2. Aged 18 to 75 years; 3. ASA?-?. 4. BMI: 18-30kg/m^2. 5. Agreed to use a patient-controlled intravenous analgesia (PCIA) pump postoperatively. 6. Agreed to sign the informed consent form. 7. Agreed to undergo combined general anesthesia and nerve block.

Exclusion criteria

Exclusion criteria: 1. Coagulation disorders. 2. Cognitive impairment, or a history of psychiatric or neurological disorders. 3. Severe cardiopulmonary diseases, including, but not limited to, cardiac function class III or above, severe valvular disorders, and severe chronic obstructive pulmonary disease (COPD). 4. Long-term corticosteroid therapy. 5. Allergy to the investigational drugs. 6. Peripheral neuropathy. 7. Diabetic patients. 8. Sick Sinus Syndrome. 9. Refuse to undergo nerve block anesthesia.

Design outcomes

Primary

Measure	Time frame
The incidence of rebound tenderness within 24 hours after surgery;	—

Secondary

Measure	Time frame
The AUC of the NRS pain score over the first 48 hours postoperatively.;Time to first analgesic rescue and number of rescue events.;Cumulative opioid dose over 48 hours;Duration of nerve block;Adverse reactions such as nausea, vomiting, and respiratory depression;	—

Countries

China

Contacts

Public ContactLingyang Chen

Taizhou Hospital of Zhejiang Province

chenly@enzemed.com+86 576 85120120

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026